 The objective of this study is to evaluate if the patient-wide SUVmax on 18F-DCFPyL PETCT in locoregional and metastatic prostate cancer correlates with histopathologic Gleason score at initial biopsy. It is hypothesized that SUVmax will correlate positively with Gleason score. This is of interest because non-invasive risk stratification may be possible in the future. 